# FineHeart

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fineheart

- Industry: Medical Devices & Equipment
- Headquarters: Pessac, France
- Website: www.fineheart.fr
- Total disclosed funding: $66M
- Latest round: Series C (Dec 11, 2025)
- Investors on record: 13

## About

Based in Pessac, France, FineHeart develops innovative medical technology solutions, focusing on advanced cardiac care with its flagship product, the FlowMaker®, designed for patients with severe heart failure.FineHeart, founded in 2010 in Pessac, France, specializes in medical devices aimed at improving heart failure treatments. The founders, Arnaud Mascarell and Philippe Ritter, have a history of innovation in the healthcare sector. The company has successfully completed a Series C funding round in January 2026, raising EUR 35 million from Etchart, Groupe Pasteur Mutualité, and European Innovation Council, Doliam, IRDInov, Lurra Capital and M Capital. The round was part of a larger EUR 83 million in equity and grant funding. FineHeart S.A. specializes in developing innovative medical technology solutions for cardiology, with a primary focus on its flagship product, the FlowMaker®. This fully implantable cardiac assist device is designed to improve the treatment of patients suffering from advanced heart failure, a condition that currently has limited effective treatment options. The FlowMaker® aims to provide robust cardiac support, enhancing patients' quality of life and allowing for better management of their heart conditions. FineHeart's technology targets healthcare providers and institutions within the cardiology sector, particularly in Europe, including France, where it has received the necessary regulatory approvals to begin clinical trials. FineHeart’s commitment to addressing significant unmet needs in heart failure treatment positions it as a key player within the medical device landscape.FineHeart's revenue model revolves around the commercialization of its cardiac assist device, the FlowMaker®, primarily through partnerships with healthcare institutions and medical providers. The company engages in direct sales to hospitals and clinics, which serve as the primary end-users of its technology. The most recent revenue report for the year 2018 indicates a total revenue of EUR 0, with an EBITDA amounting to EUR -3,132,025.9, reflecting the company's focus on product development and market entry strategies rather than immediate profitability.FineHeart is set to utilize the EUR 35 million raised in January 2026 from its Series C funding to run clinical trials for its implantable heart support device, complete regulatory steps, and set up manufacturing and operations needed for patient use. The company is also planning to expand its product offerings and enhance its market presence within Europe and potentially other regions following regulatory approvals. These initiatives will support the company's aim to better serve patients with heart failure and solidify its position in the medical technology space.

## Funding rounds

- Series C, Dec 11, 2025, $41M — M Capital, IRDInov, Groupe Pasteur Mutualité, Doliam, Etchart, Lurra Capital, European Innovation Council
- Series B, Jun 1, 2021, $18M — M Capital, Broadview Ventures, Galia Gestion, Aquiti Gestion, IRDInov, Verve Ventures, Lauak SARL, Doliam
- Series A, May 17, 2016, $7.2M — Sofimac Partners, M Capital, Broadview Ventures, Galia Gestion, Aquiti Gestion, IRDInov

## Investors

- Sofimac Partners (https://capitalatlas.ai/funds/sofimac-partners) — Series A
- M Capital (https://capitalatlas.ai/funds/m-capital) — Series A, Series B, Series C
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series A, Series B
- Galia Gestion (https://capitalatlas.ai/funds/galia-gestion) — Series A, Series B
- Aquiti Gestion (https://capitalatlas.ai/funds/aquiti-gestion) — Series A, Series B
- IRDInov — Series A, Series B, Series C
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series B
- Lauak SARL — Series B
- Doliam (https://capitalatlas.ai/funds/doliam) — Series B, Series C
- Groupe Pasteur Mutualité — Series C
- Etchart (https://capitalatlas.ai/funds/etchart) — Series C
- Lurra Capital (https://capitalatlas.ai/funds/lurra-capital) — Series C
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series C